HEART HEALTH NEWS
What has the Capital Region medical community learned about the coronavirus and how might that knowledge help end this pandemic? “What’s new for all of us is that we are learning about this virus every day. Our team is quite thorough and working together to provide the best care. You may see things on the news about how hospitals were overwhelmed, that is not the case in Albany. We had extra time to get our systems in place.”
We all have a role to play in overcoming this pandemic – together. Thank you for your contribution of medical supplies to reduce the spread of the virus. Capital Cardiology continues to deliver the highest quality of care in our Albany and Troy offices.
Almost 10% of the American population is affected by diabetes. Diabetes is treatable; it does become dangerous when glucose levels are uncontrolled. Adults with diabetes are two to four times more likely to die from heart disease than adults without diabetes.
About 40 million adults in the U.S. take a statin to lower their cholesterol and to reduce their risk of heart disease, heart attack, or stroke. Dr. Robert Benton, Director of Research at Capital Cardiology Associates, explains the new research suggesting a possible anti-cancer benefit for statins.
Ten years from now, nearly half of U.S. adults will be obese if current trends continue. “Unfortunately, for myself and my colleagues, we see this increasing at an alarming rate,” commented Dr. Heather Stahura, a board-certified cardiologist at Capital Cardiology Associates. Researchers from the Harvard T.H. Chan School of Public Health stated that by 2030, 48.9% of adults nationwide will be obese. There are also concerns that obesity will impact the American economy.
The history of the Polypill began in 1999 when the idea of combining medicines to combat cardiovascular disease was first proposed. Two recent studies have shown its ability to lower blood pressure, cholesterol levels, and cardiovascular outcomes. Dr. Robert Bento, Director of Clinical Research at Capital Cardiology Associates, explains the potential of the polypill for high-risk patients.